November 24, 2023 is the week of the 5th ,............................................................................................................................................................................................. ..............

Yuansheng saw a particularly enlightening point last night: the overall valuation of stocks on the main board, ChiNext and the Science and Technology Innovation Board is on the high side, so in recent years, except for stocks that are in hot spots, other stocks have almost not risen. To put it bluntly, unless there are hot stocks in the tuyere, most of the other stocks are not rising, and they are very easy to fall................................................................................................................................................................................................................ ............... Although it is a little ugly, there is some truth in it, in the A-shares, except for the Beijing Stock Exchange, which is a value depression and a pure land, the other sectors are more people's stocks....................................................

Therefore, smart people are now fighting in the Beijing Stock Exchange.................................................................................

Yesterday, Yuansheng found a good stock through a review, which is the second medicine stock. Take a look at its subject matter---------------------------------

The company's main business is the R&D, production and sales of advanced pharmaceutical intermediates, APIs and related products, including anti-allergies, anti-thrombosis, antioxidants, gastric ulcers, antivirals, antipyretic and analgesic and ultraviolet absorbers. The company's main products are advanced pharmaceutical intermediates and related products of pranlukast, sagrelyl hydrochloride, 4-hydroxycoumarin, resveratrol, mosapride, celecoxib, biphenyl diester, dibenzoylresorcinol and other characteristic APIs, which have the characteristics of relatively complex structure, difficult research and development, high technical barriers, unique production process and high added value. The company's core management team has more than 20 years of industry experience, has accumulated a wealth of R & D technology and industrial chain resources, the company has established long-term and stable cooperative relations with downstream customers, the main product terminal markets for South Korea, Japan and other overseas markets, the end customers include South Korea Daewoong Pharmaceutical, South Korea CKD, South Korea Ildong Pharmaceutical, Japan Sumitomo Pharmaceutical, Japan Sanyo Chemical, Japan Nippon Medical Engineering and other well-known pharmaceutical enterprises. The company has pharmaceutical production licenses for pranlukast, sagreloxil hydrochloride, ganciclovir, zatrobuprofen, celecoxib, epistine hydrochloride, azinamide and other products; The company's ganciclovir API has obtained the GMP certificate of the State Food and Drug Administration, mosapride, celecoxib, itopride and biphenyl diester have cooperated with the Korean terminal API manufacturer to complete the registration of Korean API APIs, and the company and its subsidiary Shuichi Pharmaceutical have obtained the foreign manufacturer certification issued by the Japanese government. The company is a national high-tech enterprise, with a complete and professional R&D platform, independent intellectual property rights and advanced production technology, and 6 invention patents and 19 utility model patents. Since its establishment, the company has focused on the development of its main business and scientific and technological innovation, and has been recognized as "Anhui Province Specialized and New Small and Medium-sized Enterprises", "Anhui Province Innovative Pilot Enterprise", "Anhui Province Enterprise Technology Center" and "Chuzhou Engineering Technology Research Center". In September 2021, the company invested in the establishment of a holding subsidiary, Hangzhou Xiaobei, and began to lay out the CDMO business of chemical APIs and create a one-stop CDMO service platform. The company uses a professional R&D team and rich technical experience in the research and development of production processes, quality research and safety research to gradually cultivate and develop the CDMO business of chemical APIs, so as to further extend the industrial chain, expand the business model and enhance the company's competitiveness.

In the morning, the second pharmaceutical stock opened 3.93% lower, and Yuansheng was waiting.........................

The stock price fluctuated in less than 1 minute, and the second drug stock retreated to 21.31 yuan, Yuansheng decisively bought it, and finally controlled the cost at 21.95 yuan and ended the first battle of this frontier expansion.